Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) Stock Competitors & Peer Comparison
See ZYBT's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ZYBT and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ZYBT | $1.40 | -6.67% | 69.2M | -7.30 | -$0.20 | N/A |
| TAK | $19.67 | +1.13% | 62.2B | 14.16 | $1.39 | +3.59% |
| TEVA | $41.50 | +0.95% | 48.3B | 14.16 | $2.93 | N/A |
| HLN | $10.13 | +1.91% | 44.5B | 20.71 | $0.49 | +1.96% |
| ZTS | $79.38 | +1.22% | 32.8B | 12.06 | $6.58 | +2.65% |
| VTRS | $18.66 | +2.41% | 21.4B | 7.40 | $2.52 | +2.60% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $23.55 | +0.04% | 11.8B | 22.23 | $1.06 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $13.07 | +1.32% | 10.9B | 27.79 | $0.47 | +0.64% |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
ZYBT vs TAK Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, TAK has a market cap of 62.2B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while TAK trades at $19.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas TAK's P/E ratio is 14.16. In terms of profitability, ZYBT's ROE is -0.27%, compared to TAK's ROE of +0.02%. Regarding short-term risk, ZYBT is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check TAK's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
ZYBT vs TEVA Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, TEVA has a market cap of 48.3B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while TEVA trades at $41.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas TEVA's P/E ratio is 14.16. In terms of profitability, ZYBT's ROE is -0.27%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, ZYBT is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check TEVA's competition here
Haleon plc (NYSE: HLN)
ZYBT vs HLN Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, HLN has a market cap of 44.5B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while HLN trades at $10.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas HLN's P/E ratio is 20.71. In terms of profitability, ZYBT's ROE is -0.27%, compared to HLN's ROE of +0.10%. Regarding short-term risk, ZYBT is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check HLN's competition here
Zoetis Inc. (NYSE: ZTS)
ZYBT vs ZTS Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, ZTS has a market cap of 32.8B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while ZTS trades at $79.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas ZTS's P/E ratio is 12.06. In terms of profitability, ZYBT's ROE is -0.27%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, ZYBT is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
ZYBT vs VTRS Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, VTRS has a market cap of 21.4B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while VTRS trades at $18.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas VTRS's P/E ratio is 7.40. In terms of profitability, ZYBT's ROE is -0.27%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, ZYBT is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
ZYBT vs ITCI Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas ITCI's P/E ratio is -180.64. In terms of profitability, ZYBT's ROE is -0.27%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, ZYBT is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
ZYBT vs ELAN Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, ELAN has a market cap of 11.8B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while ELAN trades at $23.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas ELAN's P/E ratio is 22.23. In terms of profitability, ZYBT's ROE is -0.27%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, ZYBT is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ELAN's competition here
Catalent, Inc. (NYSE: CTLT)
ZYBT vs CTLT Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ZYBT's ROE is -0.27%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, ZYBT is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check CTLT's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
ZYBT vs RDY Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, RDY has a market cap of 10.9B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while RDY trades at $13.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas RDY's P/E ratio is 27.79. In terms of profitability, ZYBT's ROE is -0.27%, compared to RDY's ROE of +0.09%. Regarding short-term risk, ZYBT is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
ZYBT vs ALKS Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, ALKS has a market cap of 6.9B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while ALKS trades at $41.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas ALKS's P/E ratio is 43.39. In terms of profitability, ZYBT's ROE is -0.27%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, ZYBT is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ALKS's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
ZYBT vs LNTH Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, LNTH has a market cap of 6.5B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while LNTH trades at $99.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas LNTH's P/E ratio is 16.76. In terms of profitability, ZYBT's ROE is -0.27%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, ZYBT is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
ZYBT vs AMRX Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, AMRX has a market cap of 6.1B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while AMRX trades at $19.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas AMRX's P/E ratio is 21.31. In terms of profitability, ZYBT's ROE is -0.27%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, ZYBT is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check AMRX's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
ZYBT vs RGC Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, RGC has a market cap of 4.8B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while RGC trades at $9.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas RGC's P/E ratio is -959.00. In terms of profitability, ZYBT's ROE is -0.27%, compared to RGC's ROE of -1.61%. Regarding short-term risk, ZYBT is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for ZYBT.Check RGC's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
ZYBT vs INDV Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, INDV has a market cap of 4B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while INDV trades at $32.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas INDV's P/E ratio is 8.89. In terms of profitability, ZYBT's ROE is -0.27%, compared to INDV's ROE of -2.16%. Regarding short-term risk, ZYBT is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check INDV's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
ZYBT vs HCM Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, HCM has a market cap of 2.5B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while HCM trades at $14.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas HCM's P/E ratio is 135.88. In terms of profitability, ZYBT's ROE is -0.27%, compared to HCM's ROE of +0.01%. Regarding short-term risk, ZYBT is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check HCM's competition here
Alvotech (NASDAQ: ALVOW)
ZYBT vs ALVOW Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, ALVOW has a market cap of 2.4B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while ALVOW trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas ALVOW's P/E ratio is 37.90. In terms of profitability, ZYBT's ROE is -0.27%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, ZYBT is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ALVOW's competition here
Bausch Health Companies Inc. (NYSE: BHC)
ZYBT vs BHC Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while BHC trades at $6.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas BHC's P/E ratio is 1.60. In terms of profitability, ZYBT's ROE is -0.27%, compared to BHC's ROE of +0.89%. Regarding short-term risk, ZYBT is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check BHC's competition here
Perrigo Company plc (NYSE: PRGO)
ZYBT vs PRGO Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, PRGO has a market cap of 2.3B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while PRGO trades at $16.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas PRGO's P/E ratio is 6.65. In terms of profitability, ZYBT's ROE is -0.27%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, ZYBT is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check PRGO's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
ZYBT vs DCPH Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ZYBT's ROE is -0.27%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, ZYBT is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check DCPH's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
ZYBT vs SUPN Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, SUPN has a market cap of 2.2B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while SUPN trades at $37.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas SUPN's P/E ratio is 12.38. In terms of profitability, ZYBT's ROE is -0.27%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, ZYBT is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check SUPN's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
ZYBT vs AVDL Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, ZYBT's ROE is -0.27%, compared to AVDL's ROE of +0.10%. Regarding short-term risk, ZYBT is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
ZYBT vs EMBCV Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ZYBT's ROE is -0.27%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, ZYBT is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for ZYBT.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
ZYBT vs DVAX Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas DVAX's P/E ratio is -41.89. In terms of profitability, ZYBT's ROE is -0.27%, compared to DVAX's ROE of +0.09%. Regarding short-term risk, ZYBT is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check DVAX's competition here
Alvotech (NASDAQ: ALVO)
ZYBT vs ALVO Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, ALVO has a market cap of 1.8B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while ALVO trades at $5.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas ALVO's P/E ratio is -8.47. In terms of profitability, ZYBT's ROE is -0.27%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, ZYBT is more volatile compared to ALVO. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ALVO's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
ZYBT vs TRLV Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, TRLV has a market cap of 1.7B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while TRLV trades at $10.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas TRLV's P/E ratio is -4.07. In terms of profitability, ZYBT's ROE is -0.27%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, ZYBT is more volatile compared to TRLV. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check TRLV's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
ZYBT vs ANIP Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while ANIP trades at $72.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas ANIP's P/E ratio is 8.79. In terms of profitability, ZYBT's ROE is -0.27%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, ZYBT is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
ZYBT vs TARO Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas TARO's P/E ratio is 30.05. In terms of profitability, ZYBT's ROE is -0.27%, compared to TARO's ROE of +0.03%. Regarding short-term risk, ZYBT is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
ZYBT vs PAHC Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, PAHC has a market cap of 1.6B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while PAHC trades at $38.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas PAHC's P/E ratio is 13.25. In terms of profitability, ZYBT's ROE is -0.27%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, ZYBT is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check PAHC's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
ZYBT vs PCRX Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, PCRX has a market cap of 1.4B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while PCRX trades at $36.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas PCRX's P/E ratio is 13.98. In terms of profitability, ZYBT's ROE is -0.27%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, ZYBT is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check PCRX's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
ZYBT vs ETON Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, ETON has a market cap of 1.4B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while ETON trades at $50.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas ETON's P/E ratio is 132.34. In terms of profitability, ZYBT's ROE is -0.27%, compared to ETON's ROE of +0.40%. Regarding short-term risk, ZYBT is more volatile compared to ETON. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ETON's competition here
Cronos Group Inc. (NASDAQ: CRON)
ZYBT vs CRON Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while CRON trades at $3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas CRON's P/E ratio is 16.44. In terms of profitability, ZYBT's ROE is -0.27%, compared to CRON's ROE of +0.06%. Regarding short-term risk, ZYBT is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check CRON's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
ZYBT vs AMPH Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, AMPH has a market cap of 1.1B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while AMPH trades at $25.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas AMPH's P/E ratio is 8.83. In terms of profitability, ZYBT's ROE is -0.27%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, ZYBT is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check AMPH's competition here
Harrow Health, Inc. (NASDAQ: HROW)
ZYBT vs HROW Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, HROW has a market cap of 1B. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while HROW trades at $27.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas HROW's P/E ratio is -27.56. In terms of profitability, ZYBT's ROE is -0.27%, compared to HROW's ROE of -1.04%. Regarding short-term risk, ZYBT is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check HROW's competition here
PetIQ, Inc. (NASDAQ: PETQ)
ZYBT vs PETQ Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ZYBT's ROE is -0.27%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, ZYBT is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
ZYBT vs COLL Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, COLL has a market cap of 755M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while COLL trades at $23.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas COLL's P/E ratio is 2.91. In terms of profitability, ZYBT's ROE is -0.27%, compared to COLL's ROE of +0.16%. Regarding short-term risk, ZYBT is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
ZYBT vs IRWD Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, IRWD has a market cap of 578.3M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while IRWD trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas IRWD's P/E ratio is 4.49. In terms of profitability, ZYBT's ROE is -0.27%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, ZYBT is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check IRWD's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
ZYBT vs BDSI Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ZYBT's ROE is -0.27%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ZYBT is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check BDSI's competition here
Evotec SE (NASDAQ: EVO)
ZYBT vs EVO Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, EVO has a market cap of 491.9M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while EVO trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas EVO's P/E ratio is -1.96. In terms of profitability, ZYBT's ROE is -0.27%, compared to EVO's ROE of -0.27%. Regarding short-term risk, ZYBT is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check EVO's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
ZYBT vs AQST Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, AQST has a market cap of 473.8M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while AQST trades at $3.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas AQST's P/E ratio is -5.81. In terms of profitability, ZYBT's ROE is -0.27%, compared to AQST's ROE of +2.44%. Regarding short-term risk, ZYBT is more volatile compared to AQST. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check AQST's competition here
Evolus, Inc. (NASDAQ: EOLS)
ZYBT vs EOLS Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, EOLS has a market cap of 468.3M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while EOLS trades at $7.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas EOLS's P/E ratio is -22.45. In terms of profitability, ZYBT's ROE is -0.27%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, ZYBT is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check EOLS's competition here
Kamada Ltd. (NASDAQ: KMDA)
ZYBT vs KMDA Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, KMDA has a market cap of 446.6M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while KMDA trades at $7.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas KMDA's P/E ratio is 20.37. In terms of profitability, ZYBT's ROE is -0.27%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, ZYBT is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
ZYBT vs TKNO Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, TKNO has a market cap of 380.1M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while TKNO trades at $7.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas TKNO's P/E ratio is -22.84. In terms of profitability, ZYBT's ROE is -0.27%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, ZYBT is more volatile compared to TKNO. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check TKNO's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
ZYBT vs TLRY Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, TLRY has a market cap of 340M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while TLRY trades at $3.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas TLRY's P/E ratio is -2.17. In terms of profitability, ZYBT's ROE is -0.27%, compared to TLRY's ROE of -0.09%. Regarding short-term risk, ZYBT is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check TLRY's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
ZYBT vs EBS Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, EBS has a market cap of 326.9M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while EBS trades at $6.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas EBS's P/E ratio is 4.43. In terms of profitability, ZYBT's ROE is -0.27%, compared to EBS's ROE of -0.36%. Regarding short-term risk, ZYBT is more volatile compared to EBS. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check EBS's competition here
Canopy Growth Corporation (NASDAQ: CGC)
ZYBT vs CGC Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, CGC has a market cap of 301.7M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while CGC trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas CGC's P/E ratio is -1.60. In terms of profitability, ZYBT's ROE is -0.27%, compared to CGC's ROE of -0.33%. Regarding short-term risk, ZYBT is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check CGC's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
ZYBT vs ALIM Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ZYBT's ROE is -0.27%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, ZYBT is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ALIM's competition here
Glass House Brands Inc (NYSE: GLAS)
ZYBT vs GLAS Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, GLAS has a market cap of 279.8M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while GLAS trades at $3.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas GLAS's P/E ratio is -5.68. In terms of profitability, ZYBT's ROE is -0.27%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, ZYBT is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for ZYBT.Check GLAS's competition here
Landec Corporation (NASDAQ: LNDC)
ZYBT vs LNDC Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ZYBT's ROE is -0.27%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, ZYBT is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
ZYBT vs ACB Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, ACB has a market cap of 252.6M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while ACB trades at $3.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas ACB's P/E ratio is -2.88. In terms of profitability, ZYBT's ROE is -0.27%, compared to ACB's ROE of -0.21%. Regarding short-term risk, ZYBT is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ACB's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
ZYBT vs LFCR Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, LFCR has a market cap of 241.8M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while LFCR trades at $6.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas LFCR's P/E ratio is -5.02. In terms of profitability, ZYBT's ROE is -0.27%, compared to LFCR's ROE of -3.77%. Regarding short-term risk, ZYBT is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check LFCR's competition here
Shineco, Inc. (NASDAQ: TYHT)
ZYBT vs TYHT Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ZYBT's ROE is -0.27%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, ZYBT is more volatile compared to TYHT. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
ZYBT vs SIGA Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, SIGA has a market cap of 227.8M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while SIGA trades at $3.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas SIGA's P/E ratio is 11.74. In terms of profitability, ZYBT's ROE is -0.27%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, ZYBT is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check SIGA's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
ZYBT vs REPH Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas REPH's P/E ratio is -8.04. In terms of profitability, ZYBT's ROE is -0.27%, compared to REPH's ROE of -0.22%. Regarding short-term risk, ZYBT is more volatile compared to REPH. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check REPH's competition here
Theratechnologies Inc. (NASDAQ: THTX)
ZYBT vs THTX Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas THTX's P/E ratio is -28.83. In terms of profitability, ZYBT's ROE is -0.27%, compared to THTX's ROE of +0.36%. Regarding short-term risk, ZYBT is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
ZYBT vs ASRT Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas ASRT's P/E ratio is -7.10. In terms of profitability, ZYBT's ROE is -0.27%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, ZYBT is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ASRT's competition here
Journey Medical Corporation (NASDAQ: DERM)
ZYBT vs DERM Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, DERM has a market cap of 139.9M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while DERM trades at $4.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas DERM's P/E ratio is -22.52. In terms of profitability, ZYBT's ROE is -0.27%, compared to DERM's ROE of -0.20%. Regarding short-term risk, ZYBT is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check DERM's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
ZYBT vs CRDL Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, CRDL has a market cap of 132.7M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while CRDL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas CRDL's P/E ratio is -4.38. In terms of profitability, ZYBT's ROE is -0.27%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, ZYBT is more volatile compared to CRDL. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check CRDL's competition here
Organigram Global Inc. (NASDAQ: OGI)
ZYBT vs OGI Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, OGI has a market cap of 130.9M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while OGI trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas OGI's P/E ratio is 2.09. In terms of profitability, ZYBT's ROE is -0.27%, compared to OGI's ROE of +0.21%. Regarding short-term risk, ZYBT is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check OGI's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
ZYBT vs ORGO Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, ORGO has a market cap of 128.6M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while ORGO trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas ORGO's P/E ratio is 33.32. In terms of profitability, ZYBT's ROE is -0.27%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, ZYBT is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for ZYBT.Check ORGO's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
ZYBT vs SCTL Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ZYBT's ROE is -0.27%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, ZYBT is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
ZYBT vs BGM Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, BGM has a market cap of 110.3M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while BGM trades at $8.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas BGM's P/E ratio is -1.81. In terms of profitability, ZYBT's ROE is -0.27%, compared to BGM's ROE of -0.05%. Regarding short-term risk, ZYBT is more volatile compared to BGM. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check BGM's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
ZYBT vs CPIX Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, CPIX has a market cap of 107.6M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while CPIX trades at $7.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas CPIX's P/E ratio is -17.95. In terms of profitability, ZYBT's ROE is -0.27%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, ZYBT is more volatile compared to CPIX. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check CPIX's competition here
Procaps Group S.A. (NASDAQ: PROC)
ZYBT vs PROC Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas PROC's P/E ratio is 1.53. In terms of profitability, ZYBT's ROE is -0.27%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ZYBT is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
ZYBT vs OPTN Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ZYBT's ROE is -0.27%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, ZYBT is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
ZYBT vs ZOM Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ZYBT's ROE is -0.27%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, ZYBT is more volatile compared to ZOM. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
ZYBT vs GRVI Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ZYBT's ROE is -0.27%, compared to GRVI's ROE of -4.51%. Regarding short-term risk, ZYBT is more volatile compared to GRVI. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check GRVI's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
ZYBT vs ZYNE Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, ZYBT's ROE is -0.27%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, ZYBT is more volatile compared to ZYNE. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
ZYBT vs SSIC Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ZYBT's ROE is -0.27%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, ZYBT is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
ZYBT vs VLNS Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ZYBT's ROE is -0.27%, compared to VLNS's ROE of N/A. Regarding short-term risk, ZYBT is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
ZYBT vs DRRX Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas DRRX's P/E ratio is -4.44. In terms of profitability, ZYBT's ROE is -0.27%, compared to DRRX's ROE of -0.70%. Regarding short-term risk, ZYBT is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check DRRX's competition here
Talphera, Inc. (NASDAQ: TLPH)
ZYBT vs TLPH Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, TLPH has a market cap of 56.1M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while TLPH trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas TLPH's P/E ratio is -4.00. In terms of profitability, ZYBT's ROE is -0.27%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, ZYBT is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check TLPH's competition here
InterCure Ltd. (NASDAQ: INCR)
ZYBT vs INCR Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, INCR has a market cap of 54.1M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while INCR trades at $4.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas INCR's P/E ratio is -4.81. In terms of profitability, ZYBT's ROE is -0.27%, compared to INCR's ROE of -0.09%. Regarding short-term risk, ZYBT is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
ZYBT vs JUPW Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ZYBT's ROE is -0.27%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, ZYBT is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for ZYBT.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
ZYBT vs QLI Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas QLI's P/E ratio is -4.92. In terms of profitability, ZYBT's ROE is -0.27%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ZYBT is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
ZYBT vs HEXO Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ZYBT's ROE is -0.27%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ZYBT is more volatile compared to HEXO. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check HEXO's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
ZYBT vs RMTI Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, RMTI has a market cap of 29.9M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while RMTI trades at $7.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas RMTI's P/E ratio is -5.54. In terms of profitability, ZYBT's ROE is -0.27%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, ZYBT is more volatile compared to RMTI. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check RMTI's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
ZYBT vs CPHI Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, CPHI has a market cap of 29.4M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while CPHI trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas CPHI's P/E ratio is -1.59. In terms of profitability, ZYBT's ROE is -0.27%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, ZYBT is more volatile compared to CPHI. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check CPHI's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
ZYBT vs SHPH Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, SHPH has a market cap of 24.3M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while SHPH trades at $5.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas SHPH's P/E ratio is -0.24. In terms of profitability, ZYBT's ROE is -0.27%, compared to SHPH's ROE of -1.57%. Regarding short-term risk, ZYBT is more volatile compared to SHPH. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check SHPH's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
ZYBT vs CYTH Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ZYBT's ROE is -0.27%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, ZYBT is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check CYTH's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
ZYBT vs AYTU Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, AYTU has a market cap of 22.1M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while AYTU trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas AYTU's P/E ratio is -1.72. In terms of profitability, ZYBT's ROE is -0.27%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, ZYBT is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
ZYBT vs TXMD Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, TXMD has a market cap of 22M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while TXMD trades at $1.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas TXMD's P/E ratio is 96.79. In terms of profitability, ZYBT's ROE is -0.27%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, ZYBT is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check TXMD's competition here
Optimi Health Corp. (NASDAQ: OPTH)
ZYBT vs OPTH Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, OPTH has a market cap of 19.4M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while OPTH trades at $3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas OPTH's P/E ratio is -2.17. In terms of profitability, ZYBT's ROE is -0.27%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, ZYBT is more volatile compared to OPTH. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check OPTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
ZYBT vs EVOK Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas EVOK's P/E ratio is -7.97. In terms of profitability, ZYBT's ROE is -0.27%, compared to EVOK's ROE of -0.70%. Regarding short-term risk, ZYBT is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check EVOK's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
ZYBT vs ACRX Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ZYBT's ROE is -0.27%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, ZYBT is more volatile compared to ACRX. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
ZYBT vs CABR Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, CABR has a market cap of 11.2M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while CABR trades at $1.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas CABR's P/E ratio is -1.58. In terms of profitability, ZYBT's ROE is -0.27%, compared to CABR's ROE of -3.86%. Regarding short-term risk, ZYBT is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for ZYBT.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
ZYBT vs AGRX Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ZYBT's ROE is -0.27%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, ZYBT is more volatile compared to AGRX. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
ZYBT vs NLTX Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas NLTX's P/E ratio is -0.28. In terms of profitability, ZYBT's ROE is -0.27%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, ZYBT is more volatile compared to NLTX. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
ZYBT vs LCI Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas LCI's P/E ratio is -0.04. In terms of profitability, ZYBT's ROE is -0.27%, compared to LCI's ROE of +1.66%. Regarding short-term risk, ZYBT is more volatile compared to LCI. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
ZYBT vs ADMP Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas ADMP's P/E ratio is -0.08. In terms of profitability, ZYBT's ROE is -0.27%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, ZYBT is more volatile compared to ADMP. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ADMP's competition here
InMed Pharmaceuticals Inc. (NASDAQ: INM)
ZYBT vs INM Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, INM has a market cap of 7.3M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while INM trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas INM's P/E ratio is -0.43. In terms of profitability, ZYBT's ROE is -0.27%, compared to INM's ROE of -1.35%. Regarding short-term risk, ZYBT is more volatile compared to INM. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check INM's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
ZYBT vs SNOA Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, SNOA has a market cap of 5.5M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while SNOA trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas SNOA's P/E ratio is -1.04. In terms of profitability, ZYBT's ROE is -0.27%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, ZYBT is more volatile compared to SNOA. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check SNOA's competition here
Mallinckrodt plc (AMEX: MNK)
ZYBT vs MNK Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas MNK's P/E ratio is -0.44. In terms of profitability, ZYBT's ROE is -0.27%, compared to MNK's ROE of -0.36%. Regarding short-term risk, ZYBT is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for ZYBT.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
ZYBT vs FLGC Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas FLGC's P/E ratio is -0.19. In terms of profitability, ZYBT's ROE is -0.27%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, ZYBT is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for ZYBT.Check FLGC's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
ZYBT vs GELS Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, GELS has a market cap of 4.2M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while GELS trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas GELS's P/E ratio is -1.05. In terms of profitability, ZYBT's ROE is -0.27%, compared to GELS's ROE of -0.25%. Regarding short-term risk, ZYBT is more volatile compared to GELS. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check GELS's competition here
cbdMD, Inc. (AMEX: YCBD)
ZYBT vs YCBD Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, YCBD has a market cap of 3.8M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while YCBD trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas YCBD's P/E ratio is -0.84. In terms of profitability, ZYBT's ROE is -0.27%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, ZYBT is more volatile compared to YCBD. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check YCBD's competition here
Akanda Corp. (NASDAQ: AKAN)
ZYBT vs AKAN Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, AKAN has a market cap of 2.9M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while AKAN trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas AKAN's P/E ratio is -0.03. In terms of profitability, ZYBT's ROE is -0.27%, compared to AKAN's ROE of +3.92%. Regarding short-term risk, ZYBT is more volatile compared to AKAN. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check AKAN's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
ZYBT vs PLXP Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas PLXP's P/E ratio is -0.22. In terms of profitability, ZYBT's ROE is -0.27%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, ZYBT is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for ZYBT.Check PLXP's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
ZYBT vs UPC Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, UPC has a market cap of 2.5M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while UPC trades at $3.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas UPC's P/E ratio is -0.49. In terms of profitability, ZYBT's ROE is -0.27%, compared to UPC's ROE of -0.03%. Regarding short-term risk, ZYBT is more volatile compared to UPC. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check UPC's competition here
Athenex, Inc. (NASDAQ: ATNX)
ZYBT vs ATNX Comparison October 2026
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYBT stands at 69.2M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, ZYBT is priced at $1.40 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYBT currently has a P/E ratio of -7.30, whereas ATNX's P/E ratio is -0.02. In terms of profitability, ZYBT's ROE is -0.27%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, ZYBT is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ATNX's competition here